What Анаприлин treats: Main Uses and Benefits

The therapeutic application of Анаприлин (Propranolol) is focused on providing supportive management for symptoms related to heightened physiological activity across relevant therapeutic areas. It is commonly used to help with symptoms that create noticeable interference with daily functioning.

This medication is relevant in contexts of chronic management, where it is commonly used to help with conditions characterized by periods of heightened symptoms, including sustained high blood pressure (Hypertension), Angina Pectoris, and various irregular heart rhythms (Arrhythmias). It may be part of symptomatic management in prophylactic regimens to decrease the frequency of recurrent Migraine Headaches and for managing the involuntary rhythmic shaking of Essential Tremor. It is also relevant in clinical settings that involve acute or unstable symptom patterns, to assist with easing the physical manifestations of Thyrotoxicosis and intense situational anxiety. This supportive relief helps patients cope more steadily with difficult episodes.

Quick Fact: Relief for Physical Signs of Stress

“It is applied to ease challenging symptoms that become difficult to tolerate, providing supportive therapeutic benefit during phases of increased distress or discomfort.”

Regulatory References

1. NIH MedlinePlus overview

The official regulatory eligibility for Анаприлин (Propranolol) is determined by its classification as a non-selective beta-blocker, leading to specific exclusions and restrictions based on physiological and comorbidity status.

Populations for whom use is Contraindicated

Use is strictly prohibited in patients with a history of bronchial asthma or bronchospasm. It is also contraindicated in severe cardiac conditions, including cardiogenic shock, sinus bradycardia, and second- or third-degree heart block (unless a pacemaker is present), or uncontrolled congestive heart failure.

Age-Related and Condition-Specific Eligibility

Population Group	Eligibility Status (Regulatory Basis)
Adults	Established use for approved indications.
Infants	Use is contraindicated if corrected age is less than five weeks or weight is less than 2 kg.
Geriatrics	Use is permitted, but the dosage requires careful, individual determination.
Hepatic/Renal Impairment	Use requires caution due to slower drug clearance, which may increase exposure.
Diabetes/Fasting	Use requires caution as the medicine can mask the early signs of hypoglycemia.
Pregnancy/Lactation	Pregnancy Category C. Use is generally not recommended unless essential; breastfeeding is also not recommended by some official sources.

Regulatory documents define who can use the drug based on the severity of underlying cardiovascular, respiratory, and metabolic conditions, ensuring the drug's core actions do not compromise critical body functions.

Interactions with other medicines and products

The interaction profile of Anaprilin (Propranolol) is defined by its metabolism through multiple cytochrome P450 (CYP) enzymes and its effects on the cardiovascular system, which may be compounded by co-administered agents. All statements below reflect documented information from official government regulatory sources.

Pharmacokinetic Interactions: Exposure Modification

Co-administration with inhibitors of CYP2D6, CYP1A2, and CYP2C19 (e.g., Fluoxetine, Cimetidine, Fluconazole) increases systemic exposure to Propranolol, leading to elevated plasma concentrations. Conversely, CYP inducers (e.g., Rifampin) decrease plasma levels, potentially resulting in a loss of efficacy. Separately, agents like Cholestyramine significantly reduce the absorption of Propranolol, decreasing systemic exposure.

Pharmacodynamic and Substance Interactions

Interaction Type	Interacting Agents	Official Restriction/Effect
Contraindicated Combination	Non-dihydropyridine calcium channel blockers (e.g., Verapamil, Diltiazem)	Strictly prohibited due to risk of severe bradycardia and cardiac depression.
Reinforced Cardiac Effects	Digoxin, Class 1 anti-arrhythmic agents	Risk of increased atrio-ventricular conduction time and myocardial depression.
Substance Interaction	Alcohol, Cigarette Smoking	Alcohol may increase exposure; smoking decreases clearance through enzyme induction.

Administration Requirements

Specific timing rules are documented for certain high-risk combinations. When discontinuing Clonidine, Propranolol must be withdrawn several days prior to avoid rebound hypertension. Additionally, intravenous administration of non-dihydropyridine calcium channel blockers is restricted within 48 hours of discontinuing Propranolol.

Sympatholytic Action on Cardiac beta1 Receptors

This primary domain focuses on competitive antagonism of the beta1 adrenergic receptors, predominantly in the heart. By blocking the binding of stimulating catecholamines like norepinephrine, the drug slows the natural pacemaker rhythm and reduces the force of muscle contraction, leading to negative chronotropy and negative inotropy.

Systemic Modulator: beta2 Blockade and Renin Suppression

The non-selective nature of the drug extends its action to beta2 receptors in the bronchial and vascular smooth muscle, simultaneously limiting the body's natural bronchodilatory response. Furthermore, beta1 blockade on the kidneys reduces renin release, contributing to the modulation of vascular tone and systemic pressure dynamics through the RAAS pathway.

Central and Ancillary Effects

Due to its high lipophilicity, the molecule readily crosses the blood-brain barrier to modulate central nervous system pathways. This central activity, coupled with the peripheral beta2 blockade on skeletal muscle, engages mechanisms that modulate sympathetic signaling effects on skeletal muscle, influencing autonomic motor responses.

How to use Анаприлин: Official Administration Guidelines

The usage of Анаприлин (Propranolol) follows established protocols detailing the administration route, schedule, and procedural steps. The medicine is utilized primarily via the oral route (tablets or capsules) for standard maintenance therapy, but is also available as a sterile solution for intravenous injection reserved for specialized, acute hospital settings.

---

Dosing and Frequency Structure

Therapy is initiated with a low starting dose followed by a required gradual upward titration conducted by a prescribing professional. Maintenance dosing typically falls within the range of 80 mg to 320 mg total per day, with specific maximum limits applying to different indications. The frequency pattern is determined by the formulation: Immediate-Release forms are administered in divided doses (two to four times daily), while Extended-Release forms are designed for once-daily use.

---

Administration Conditions and Protocols

Oral formulations may be taken consistently either with or without food. Crucially, the Extended-Release capsule must be swallowed whole and cannot be crushed, chewed, or opened. For older adults and patients with hepatic or renal impairment, treatment is typically initiated with the lowest available dose. The medicine is used as a component of long-term therapy, and if discontinuation is required, the dose is formally tapered (gradually reduced) over a period of seven to fourteen days; abrupt cessation is not part of the official procedural protocol.

Research evidence / Overview of studies for Анаприлин

This section describes the types of clinical research that have been conducted for Анаприлин (Propranolol), what outcomes these studies monitored, and where the evidence base remains limited, according to official regulatory and scientific sources.

---

1. Evidence from Studies on Cardiovascular and Neurological Uses (High Blood Pressure, Angina, and Tremor)

This section will summarize the structure of clinical research, including the foundational randomized controlled trials (RCTs) and systematic reviews, that explored whether the medicine was associated with patterns related to sustained high blood pressure, angina pectorus, and essential tremor.

1.1. Research on Sustained High Blood Pressure

Research into the use of Анаприлин for sustained high blood pressure was evaluated in numerous historical Randomized Controlled Trials (RCTs) and large observational cohort studies. These studies primarily monitored the change in systolic and diastolic blood pressure across the studied time intervals. Data from long-term observational studies describe patterns observed in the studies related to the association between the medicine's use and cardiovascular outcomes. However, certainty remains low for some aspects, as comprehensive, prospective RCT data characterizing its use against newer therapies are still emerging.

1.2. Research on Angina Pectoris and Essential Tremor

For Angina Pectoris, the research included Historical Prospective Studies that was evaluated in adults with stable angina. These studies monitored outcomes related to the frequency and severity of anginal episodes. For Essential Tremor, Double-Blind RCTs and Crossover Trials was studied for outcomes reflecting daily functioning and outcomes related to physical discomfort. A key limitation is that much of the foundational evidence for angina is historical, relying on older study designs, and the evidence for Essential Tremor does not fully characterize the potential for the maintenance of observed outcomes over many years.

---

2. Evidence from Studies on Migraine Prevention and Symptomatic Relief

2.1. Research on Migraine Prophylaxis

The evidence base is composed of Double-Blind, Placebo-Controlled RCTs and subsequent Systematic Reviews. Studies reported a consistent pattern of findings regarding the measured change in the frequency of migraine attacks. However, comparative evidence is lacking in some head-to-head trials against all alternative preventative medications, and follow-up durations were limited in some studies assessing the consistency of observed outcomes over extended time periods.

2.2. Research on Symptomatic Relief of Physical Manifestations

The research for symptomatic relief was observed in smaller Short-Term Trials, relevant in trials assessing short-term or episodic symptom patterns. Research highlights the outcomes related to physical discomfort that were measured during the study period. The findings were mixed for outcomes related to physical discomfort, and data for using this medicine specifically for generalized, non-somatic anxiety symptoms remain insufficient.

---

3. Evidence in Specialized and Pediatric Populations (Infantile Hemangioma)

Research for this specific use was conducted through Pivotal Phase 2–3 Randomized, Placebo-Controlled Trials in infants with proliferating hemangioma. Pivotal randomized trials described patterns in the measured rate of change in the lesion when comparing the study drug group to the placebo group. This research provides context that applies only to the populations studied—specifically, infants. This is a relatively newer evidence base; therefore, long-term effects are not fully established, and research is ongoing regarding potential long-term neurodevelopmental associations.

---

5. Identifying Research Gaps and Uncertainties

The evidence base, while extensive, contains several gaps. For many indications, comparative evidence is lacking in modern, high-powered trials that directly compare Анаприлин against all available alternative therapies. Data for certain groups remain insufficient, such as those with certain comorbid conditions or specific demographics within the elderly population for some indications. The research provides context but does not determine whether an individual will respond similarly to the group patterns observed in the studies.

Key Studies & References

1. Propranolol Hydrochloride Tablets Official FDA Labeling Information (DailyMed)
2. WHO Model List of Essential Medicines (Propranolol inclusion)

Common questions about Анаприлин (FAQ)

Q: Can I drink alcohol while taking this medicine?

Official product information advises patients to avoid drinking alcohol while taking this medicine. Both alcohol and this medication can affect the central nervous system. Combining them can increase CNS-related side effects, such as severe sleepiness, dizziness, or difficulty concentrating.

Q: What should I do if I am pregnant or plan to become pregnant?

Regulatory documents indicate that this medicine is not generally recommended for use during pregnancy due to potential risk of harm to the fetus. Women of childbearing potential are advised in regulatory documents to use effective contraception while taking this medicine. Official information also advises against breastfeeding during treatment.

Q: What is the most serious side effect I should watch out for?

The most serious reported effect is a severe allergic reaction, known as hypersensitivity or angioedema. In the event of symptoms such as swelling of the face, lips, tongue, or throat, or difficulty breathing, emergency medical attention should be sought immediately. These symptoms are listed in official safety information as reasons to stop treatment right away.

Q: Does this medicine cause mood swings or changes in thinking?

Official regulatory documents list several central nervous system effects, including changes in mood and thinking. Side effects such as confusion, irritability, euphoric mood, and disorientation have been reported by patients. Furthermore, this medication carries a warning regarding an increased risk of suicidal thoughts or behavior.

Q: Where should I store my medication?

According to the official product information, the medication should be stored in the original container at room temperature, typically between 68 F and 77 F (20 C and 25 C). It must be kept protected from both heat and moisture to maintain its quality and stability.

Q: Is it safe to stop taking this medicine suddenly?

Stopping treatment abruptly is not recommended according to regulatory warnings. Doing so can increase the risk of seizures or lead to unpleasant withdrawal reactions like headache, insomnia, nausea, or anxiety. Official guidance recommends that discontinuation should be gradual, typically over a minimum of 1 week.

Q: Can children 10 years old use this medicine?

Official product information indicates that the safety and effectiveness of this medicine have not been established in patients under 12 years of age. Therefore, use in this younger pediatric population is not routinely covered by the authorization.

Q: Will this drug interact with my other medicines?

Official drug interaction data highlights a risk when this medicine is combined with other central nervous system (CNS) depressants. This includes depressants such as opioid pain medicines or other medications used for anxiety or sleep. This combination may significantly increase side effects like extreme drowsiness, breathing difficulties, and sedation.

The official regulatory requirements for Анаприлин (propranolol) define specific storage conditions to maintain its stability and effectiveness.

Storage Conditions

Requirement	Official Regulatory Statement
Temperature	Store at controlled room temperature: 20 C to 25 C (68 F to 77 F).
Restrictions	Protect from freezing and excessive heat (especially the injection solution).
Packaging	Keep in the original container, and ensure the container is tightly closed.
Child Safety	Store the medication out of the reach of children.

Disposal Instructions

Expired or unused medication should not be disposed of by flushing it down a toilet or pouring it down a drain. The preferred disposal method is using a medicine take-back program. If no take-back program is available, the product must be mixed with an undesirable substance, sealed in a bag, and discarded in the household trash.